Cell state dependent effects of Bmal1 on melanoma immunity and tumorigenicity.
Xue ZhangShishir M PantCecily C RitchHsin-Yao TangHongguang ShaoHarsh DweepYao-Yu GongRebekah BrooksPatricia BraffordAdam J WolpawYool LeeAshani WeeraratnaAmita SehgalMeenhard HerylynAndrew KossenkovDavid SpeicherPeter Karl SorgerSandro SantagataChi Van DangPublished in: Nature communications (2024)
The circadian clock regulator Bmal1 modulates tumorigenesis, but its reported effects are inconsistent. Here, we show that Bmal1 has a context-dependent role in mouse melanoma tumor growth. Loss of Bmal1 in YUMM2.1 or B16-F10 melanoma cells eliminates clock function and diminishes hypoxic gene expression and tumorigenesis, which could be rescued by ectopic expression of HIF1α in YUMM2.1 cells. By contrast, over-expressed wild-type or a transcriptionally inactive mutant Bmal1 non-canonically sequester myosin heavy chain 9 (Myh9) to increase MRTF-SRF activity and AP-1 transcriptional signature, and shift YUMM2.1 cells from a Sox10 high to a Sox9 high immune resistant, mesenchymal cell state that is found in human melanomas. Our work describes a link between Bmal1, Myh9, mouse melanoma cell plasticity, and tumor immunity. This connection may underlie cancer therapeutic resistance and underpin the link between the circadian clock, MRTF-SRF and the cytoskeleton.
Keyphrases